Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

Healthcare Industrials Auto Parts Drug Manufacturers - Specialty & Generic Diversified Industrials
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally. The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and... see more

Recent & Breaking News (TSX:HLS)

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

GlobeNewswire November 18, 2025

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Canada NewsWire November 18, 2025

HLS Therapeutics Announces Q3 2025 Financial Results

Canada NewsWire November 13, 2025

HLS Therapeutics to Host Q3 2025 Financial Results Conference Call

Canada NewsWire October 30, 2025

HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Canada NewsWire October 14, 2025

HLS Therapeutics Announces New Credit Agreement

Canada NewsWire August 20, 2025

HLS Therapeutics Announces Q2 2025 Financial Results

Canada NewsWire August 14, 2025

HLS Therapeutics to Host Q2 2025 Financial Results Conference Call

Canada NewsWire July 31, 2025

HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan

Canada NewsWire July 2, 2025

HLS Therapeutics Reports Annual Meeting Results

Canada NewsWire June 20, 2025

HLS Therapeutics Announces Q1 2025 Financial Results

Canada NewsWire May 8, 2025

HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

Canada NewsWire May 8, 2025

HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Canada NewsWire April 28, 2025

HLS Therapeutics to Host Q1 2025 Financial Results Conference Call

Canada NewsWire April 24, 2025

HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid

Canada NewsWire March 13, 2025

HLS Therapeutics Appoints Christine Elliott to its Board of Directors

Canada NewsWire March 13, 2025

HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call

Canada NewsWire February 27, 2025

10 cheap healthcare stocks to buy now

Jonathon Brown November 11, 2024

HLS Therapeutics Announces Q3 2024 Financial Results

Canada NewsWire November 7, 2024

HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

Canada NewsWire October 24, 2024